**What is known**Plexiform fibromyxoma is a rare mesenchymal tumor presumed to be a benign tumor that most commonly arises in the gastric antrum.The most important differential diagnosis with plexiform fibromyxoma is gastrointestinal stromal tumor, in which the clinical and genetic features differ between pediatric and adult patients.**What is new**All plexiform fibromyxomas demonstrate benign clinical behaviors, and the tumors grow more in pediatric patients than in adult patients.Other than tumor size, there are no pathological or clinical differences between pediatric and adult plexiform fibromyxomas, which indicates a single disease entity irrespective of onset age.

1. Introduction
===============

Plexiform fibromyxoma (PF) is a rare gastric tumor, officially recognized as a distinct entity among mesenchymal tumors in the 2010 WHO Classification of Tumours of the Digestive System.^\[[@R1]\]^ After immunohistochemical analyses became available, PF was first described as a plexiform angiomyxoid myofibroblastic tumor of the stomach in 2007.^\[[@R2]\]^ To date, there have been approximately 80 cases of PF reported.

Gastrointestinal stromal tumor (GIST), which is the most common primary mesenchymal tumor of the stomach, occurs rarely in pediatric patients, and the generally accepted definition of pediatric GIST is based on the diagnosed age of 18 years or younger.^\[[@R3]\]^ Pediatric GIST differs from adult GIST with respect to the clinical features of female predominance, gastric location, epithelioid histologic morphology, lower frequency of *KIT* or *PDGFRA* mutations, and an indolent clinical course.^\[[@R3]\]^ However, the characteristics of pediatric PF remain to be elucidated. This systematic literature review was conducted to clarify the pathological and clinical features of pediatric PF compared to adult PF.

2. Methods
==========

2.1. Criteria for considering articles for review
-------------------------------------------------

### 2.1.1. Types of studies

All types of articles that reported clinical data on PF patients were reviewed, and 1 additional case treated in our center was included in this review. This study protocol was approved by the Beppu Medical Center Ethics Committee.

### 2.1.2. Types of participants

Adult patients (19 years or older) and pediatric patients (18 years or younger) were diagnosed with PF based on histological examination showing that the tumor tissues exhibited a plexiform intramural growth pattern composed of spindle-shaped bland tumor cells with oval nuclei and abundant myxoid or fibromyxoid stroma with increased vascularity.

Cases reported as PF with potentially different diagnoses, such as GIST, schwannoma, inflammatory myofibroblastic tumor, desmoid-type fibromatosis, and myxoid soft tissue perineuroma, were excluded if the tumor cells were immunohistochemically positive for any of CD34, CD117, discovered on GIST-1 (DOG1), S100, β-catenin, anaplastic lymphoma kinase (ALK), and epithelial membrane antigen (EMA).

### 2.1.3. Types of outcome measures

In adult and pediatric PF patients separately, the outcomes included: primary outcomes (pathological features), with immunohistochemistry including vimentin, smooth muscle actin (SMA), desmin, caldesmon, muscle specific actin (HHF35), and cytokeratin; and secondary outcomes (clinical features) including sex predominance, chief complaint, tumor size (maximum diameter) of the resected specimen, tumor-related mortality, and tumor recurrence and metastasis during the follow-up period.

2.2. Electronic search methods for identification of articles
-------------------------------------------------------------

MEDLINE (1948 to March 2018) and EMBASE (1947 to March 2018) were both accessed on 13 March 2018, using the following search strategy:

1.  Plexiform fibromyxoma \[tiab\]

2.  Plexiform angiomyxoma \[tiab\]

3.  Plexiform angiomyxoid myofibroblastic tumor \[tiab\]

4.  1 OR 2 OR 3

All English language articles identified were reviewed. Reference lists of the retrieved articles were also searched to find any other relevant published data. There were no date or publication restrictions.

2.3. Data collection and analysis
---------------------------------

### 2.3.1. Article selection and data extraction

Two reviewers (MF, HK) independently reviewed the full text of identified English articles and excluded articles failing to meet the criteria. Data from identified articles that met the criteria was also independently extracted.

### 2.3.2. Dealing with missing data

Corresponding authors were contacted for missing data where possible, and primary or secondary outcomes were assessed after excluding missing values.

### 2.3.3. Data analysis

The results from articles that met the criteria were included in the analysis, and the outcomes were assessed separately for adult and pediatric PF cases. Immunohistochemically, diffusely positive or focally positive staining was considered positive expression. Data is expressed as numbers (percentage) for categorical variables and as medians (interquartile range \[IQR\]) for continuous variables. For statistical analyses, the Chi-squared test, Fisher exact test, and the Mann-Whitney *U* test were used, as applicable. All analyses were performed using SPSS Statistics Version 20 (IBM, Armonk, NY).

3. Results
==========

The electronic search identified 80 records (MEDLINE = 43, EMBASE = 37). After 23 reports were removed because of duplication, 57 reports were identified for potential inclusion. Full article assessment of 57 reports with the reference search identified 45 reports including 84 cases that met the inclusion criteria. Five cases in 4 reports were excluded because of incompatible immunohistochemistry results, such as positive for CD34 or S100.^\[[@R4]--[@R7]\]^ Including 79 PF cases in 41 reports and 1 PF case treated in our center, a total of 80 PF cases (of which 70 were adult PF and 10 were pediatric PF cases) were included in this review; they are listed in Table [1](#T1){ref-type="table"} .^\[[@R2],[@R6],[@R8]--[@R46]\]^ There was complete agreement between the review authors assessing the reports.

###### 

Details of 80 cases with immunestochemical features compatible with PF.
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###### 

Details of 80 cases with immunestochemical features compatible with PF.
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Baseline demographic and clinical characteristics of the 80 patients are shown in Table [2](#T2){ref-type="table"}. Ulcerative lesions of the tumor were observed in 65% of all patients and in 95% of those with a chief complaint indicating gastrointestinal bleeding, including hematemesis, tarry stool, and anemia. The location of the tumor was in the stomach in 94% of cases, but 6% were in other organs, such as the esophagus, duodenum, jejunum, and cecum.

###### 

Baseline demographic and clinical characteristics.
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Immunohistochemically, tumor cells were positive or focally positive for vimentin in 100% of patients examined, smooth muscle actin (SMA) in 93%, desmin in 41%, caldesmon in 57%, muscle-specific actin (HHF35) in 100%, and cytokeratin in 6% (Table [1](#T1){ref-type="table"} ). In contrast, staining for CD34, CD117, DOG1, S100, neurofilament, β-catenin, ALK, and EMA was negative in all patients examined. Ki-67 proliferation indices were assessed in 14 cases, and those of 13 (93%) were 2% or lower. All 23 cases that were analyzed for *KIT* and *PDGFRA* mutations demonstrated wild-type sequences.

Primary and secondary outcomes were compared between adult and pediatric PF cases (Table [3](#T3){ref-type="table"}). Immunohistochemical expressions of pediatric PF were not different from those of adult PF. Median tumor size of the resected specimen was larger in pediatric PF than in adult PF, but sex predominance and chief complaints were not different between the groups. No patients died of PF or had recurrence or metastasis of PF during the follow-up period.

###### 

Primary and secondary outcome measures.
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4. Discussion
=============

In summary, both adult and pediatric PF cases showed similar biological and clinical features, except for enlarged tumor size at surgical resection in pediatric PF cases. Regardless of age at onset, PF showed benign clinical behaviors, and no recurrence, metastasis, or tumor-related deaths were observed. This is the first systematic literature review to assess the age-related characteristics of PF.

The annual incidence rate of GIST was reported to be 0.68 per 100,000 in the United States.^\[[@R47]\]^ Although the epidemiology of PF remains unclear, the incidence of PF is estimated to be less than 1/150 of that of GIST,^\[[@R11]\]^ and the reported frequency of adult PF was seven times higher than of pediatric PF in the current study. Based on these data, the estimated annual incidence rate of PF is approximately 0.45 (0.40 in adult and 0.05 in pediatric PF) per 100,000,000. Thus, PF is a rare submucosal tumor, but it should be considered as a potential cause of mesenchymal tumors of the stomach, especially in the antrum.

The clinical features of pediatric GIST are similar to those of pediatric PF, characterized by commonly arising from the gastric antrum, exhibiting myxoid morphology, and the absence of *KIT* or *PDGFRA* mutations.^\[[@R3]\]^ In contrast, pediatric GIST can be immunohistologically discriminated from pediatric PF by sensitive and specific immunohistochemical markers, such as CD34, CD117, and DOG1.^\[[@R48]\]^ Similarly, several gastrointestinal tumors with histology similar to pediatric PF can be discriminated by immunohistochemical markers, such as CD34 for inflammatory fibroid polyp, S100 for gastrointestinal schwannoma, β-catenin for desmoid-type fibromatosis, ALK for inflammatory myofibroblastic tumor, and EMA for myxoid soft tissue perineuroma.^\[[@R48]\]^ Based on these pathological findings, the current study excluded atypical PFs with incompatible immunohistochemistry and included immunohistochemically compatible PFs, and the pathological and clinical features of pediatric PF were elucidated. The immunohistochemistry of pediatric PF was similar to that of adult PF with respect to positive expressions of specific markers, such as of mesenchymal cells (vimentin), muscular cells (SMA, desmin, caldesmon, and HHF35), and epithelial cells (cytokeratin). In addition, there were common clinical characteristics, such as hemorrhagic ulcer formation and a benign clinical course, shared by pediatric and adult PF cases. Therefore, the results from the present study are biologically plausible with respect to pathological and clinical compatibility. The enlarged tumor size of pediatric PF could be explained by age-related higher tumor cell proliferation and might be associated with a lower frequency of incidental diagnosis in pediatric PF than in adult PF cases. The present study showed similar pathological and clinical characteristics between pediatric and adult PF cases, unlike pediatric and adult GIST cases, and this finding suggests that PF is a single disease entity unrelated to the age at onset. PF can be treated and followed-up as a benign tumor when confirmed histologically and immunohistochemically.

This study had some limitations because of the literature review and small sample size. In view of potential unreported PF cases without severe symptoms, there might be a risk of selection bias toward overestimation of severity. However, under such conditions, there were no tumor-related deaths, recurrences, or metastases of PF, which provides the basis for considering PF a benign tumor. A population-based registry for PF is required to further investigate the epidemiology of PF.

In conclusion, both pediatric and adult PF cases showed similar pathological characteristics and benign clinical behavior, which indicates that PF is the same disease entity, regardless of onset age.
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